Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.75 USD

77.75
2,585,851

+1.08 (1.41%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $77.76 +0.01 (0.01%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.

    The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca

    The Zacks Analyst Blog Highlights: Walmart, NVIDIA, Procter & Gamble, Phillips 66 and AstraZeneca

      Cancer Space Update: Label Expansion for Three Major Drugs

      This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

        Acorda Reports Death in Parkinson's Trials, Stock Down 40%

        Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.

          AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

          AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

            Arpita Dutt headshot

            Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

            Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

              AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

              AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

                Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

                Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

                  Arpita Dutt headshot

                  Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

                  Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

                    AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

                    AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

                      Swarup Gupta headshot

                      Foreign Stock Roundup: Toyota, Gol Linhas Beat, AstraZeneca, Fresenius Miss

                      Earnings numbers continued to guide Europe's markets last week.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

                        Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                          Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up

                          Valeant (VRX) reported encouraging results for the third quarter but trimmed its guidance to reflect recent divestitures.

                            Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                            Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                              AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View

                              AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

                                It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

                                  Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                                  Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                                    Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

                                    Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

                                      Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

                                      Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

                                        Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

                                        Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

                                          Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

                                          Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.

                                            Celgene Down on Discontinued Crohn's Disease Drug Study

                                            Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.

                                              Cancer Treatment Update: Second Gene Therapy Receives Approval

                                              The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

                                                AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

                                                AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

                                                  Bristol-Myers Gets Priority Review for Opdivo Label Expansion

                                                  Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.